Women's Health

  • What are the considerations in patient selection and timing of risk-reducing mastectomy?
    Holly J. Pederson, MD, Allison W. Kurian, MD, MSc and Zahraa Al Hilli, MD
    Cleveland Clinic Journal of Medicine August 2022, 89 (8) 442-444; DOI: https://doi.org/10.3949/ccjm.89a.21114

    The option of risk-reducing mastectomy is for those at highest risk, and multidisciplinary conversations setting patient expectations are critical for optimal patient outcomes.

  • Mondor disease of the breast
    Toshiyuki Yamaguchi, MD
    Cleveland Clinic Journal of Medicine July 2022, 89 (7) 371-372; DOI: https://doi.org/10.3949/ccjm.89a.21097

    A 43-year-old woman had 2 weeks of pain and skin tightness over the right breast. Ultrasonography revealed a noncompressible, dilated, subcutaneous vein without flow.

  • Women’s health update: A literature review impacting primary care
    Brigid M. Dolan, MD, MEd, Sarah Merriam, MD, MS, Christine A. Prifti, MD and Judith M. Walsh, MD, MPH
    Cleveland Clinic Journal of Medicine July 2022, 89 (7) 373-381; DOI: https://doi.org/10.3949/ccjm.89a.21123

    The authors review cardiovascular disease, bone health, breast cancer risk, cervical cancer prevention, postpartum depression, pelvic pain, and emergency contraception.

  • A brownish erythematous patch in the nipple-areola complex
    Irene López Riquelme, MD, Elisabeth Gómez Moyano, MD, PhD, María Ayala Blanca, PhD and Leandro Martínez Pilar, MD, PhD
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 241-242; DOI: https://doi.org/10.3949/ccjm.89a.21059

    Biopsy revealed neoplastic cells throughout the epidermis and granular layer, with abundant pale cytoplasm, intraglandular extension, and chronic inflammation in the papillary dermis.

  • Managing stage 1 hypertension: Consider the risks, stop the progression
    Abel Hooker, MD, Kevin G. Buda, DO and Maarya Pasha, MD
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 244-248; DOI: https://doi.org/10.3949/ccjm.89a.21101

    Guidelines on managing patients with stage 1 hypertension and a low 10-year risk of atherosclerotic cardiovascular disease.

  • Psychogenic nonepileptic seizure: An empathetic, practical approach
    Becky Bikat S. Tilahun, PhD and Jocelyn F. Bautista, MD
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 252-259; DOI: https://doi.org/10.3949/ccjm.89a.21109

    Barriers to care include clinician misperceptions, lack of acceptance of the diagnosis, poor patient engagement with treatment, and lack of access to care.

  • Psychogenic nonepileptic seizure: A neurologist’s perspective
    Elaine Wyllie, MD
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 260-261; DOI: https://doi.org/10.3949/ccjm.89a.21129

    Confirming the diagnosis is only the start of the journey. The greater challenge and opportunity lie in how physicians present the diagnosis to the patient and family.

  • Potential systemic benefits of shocking or blocking nerves
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 119-120; DOI: https://doi.org/10.3949/ccjm.89b.03022

    What has really caught my attention is the expanding research on controlled regional neuromodulation and its impact on systemic physiology and inflammation.

  • Breast cancer risk evaluation for the primary care physician
    Christine L. Klassen, MD, Elizabeth Gilman, MD, Aparna Kaur, MD, Sara P. Lester, MD and Sandhya Pruthi, MD
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 139-146; DOI: https://doi.org/10.3949/ccjm.89a.21023

    The authors offer a systematic approach to the assessment and management of patients at risk of breast cancer.

  • Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application
    Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application
    Yeonsoo Sara Lee, BS, Christopher Wie, MD, Scott Pew, MD and Juliana M. Kling, MD, MPH
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 147-153; DOI: https://doi.org/10.3949/ccjm.89a.21032

    Hormone therapy is the mainstay of treatment, but there is a clear need for safe and effective nonhormonal options. The authors review data on the use of stellate ganglion block in perimenopausal and postmenopausal patients.

Pages